Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Under the agreement terms, Alumis will receive $40 million in upfront and near-term co-development payments, with the possibility of an additional $140 million in milestone and field option payments.

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Investing.com — Les actions d’ Alumis Inc. (NASDAQ: ALMS) ont bondi de 60% aujourd’hui suite à l’annonce d’un important accord de collaboration et de licence avec Kaken Pharmaceutical pour le développ ...